Optimization-iteration reduction success criterion
20 %
- EndpointRequired mean reduction with Dose+ assistance
- PopulationDose+ (1.0)
- Tested versionDose+ 1.0
FDA-cleared profile
Mvision AI Oy · Radiotherapy Planning Imaging · FDA-cleared (510(k))
Authorized purpose: Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Dose+ 1.0 uses locked machine-learning models to predict a patient-specific three-dimensional dose distribution for men receiving external-beam radiotherapy for localized prostate cancer or prostate cancer with pelvic-node involvement. Qualified users must review its DICOM RT Dose output in a treatment-planning system or compatible viewer.
Evidence takeaway. Evidence from the reviewed source record: FDA materials describe separate development, independent performance-verification, and four-site prospective U.S. clinical-validation datasets. Both prostate and pelvic-node models met predefined plan-quality, optimization-iteration, user-acceptance, and safety criteria; the summary does not publish all sample sizes or effect estimates.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.
20 %
K250064
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesBuild a local total-cost and value model; do not infer reimbursement from FDA clearance.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Patient CT images, RT Structure Sets, ROI names, and target dose prescription.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)
Source context, not route validation: DICOM-RT input and RT Dose export to compatible treatment-planning or review software; exact TPS compatibility requires acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0) · Dose+ product-family overview
Source context, not route validation: K250064 describes cloud service with secure HTTPS transfer or local installation in the provider network.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0) · Dose+ product-family overview
Source context, not route validation: DICOM RT Dose object containing a predicted three-dimensional dose distribution.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)
Unresolved route: DICOM RT Dose object containing a predicted three-dimensional dose distribution.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-03 · FDA 510(k) decision material K250064: Dose+ (1.0)
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Confirm the controls against the exact contracted architecture and release.
Map the installed model, build, options, population, anatomy, inputs, and outputs to K250064 before acceptance.
exact submission · checked 2026-09-03Later product-family features are not evidence that this cleared release includes them.
DICOM-RT input and RT Dose export to compatible treatment-planning or review software; exact TPS compatibility requires acceptance testing.
exact submission · checked 2026-09-03Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.
exact submission · checked 2026-09-03Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Dose+ is not a treatment-planning system, does not review a completed plan, and is not for diagnosis or treatment decisions. Predictions require qualified review in a TPS or DICOM-RT application before further use.
exact submission · checked 2026-09-03Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Twenty PubMed records and ten trial records were screened. They concern dose, drugs, or radiotherapy generally and do not identify Dose+ 1.0/K250064 as the tested release. No evidence was promoted, and all 30 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision material, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
7 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: reimbursement, radiationTherapyPaymentContext
Scope: productFamily, workflowRole, integration, deployment, security, implementationCapabilities, currentCommercialContext
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Therapanacea Sas
Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.
Therapanacea SAS
Authorized purpose: ART-Plan assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K242822. This release included Annotate and TumorBox contouring plus SmartPlan automatic prostate-plan generation for import into the treatment-planning system for dose calculation, review, and approval.
MIM Software Inc.
Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.
MIM Software Inc.
Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history